RICCIARDI, SILVIA
 Distribuzione geografica
Continente #
EU - Europa 209
NA - Nord America 188
AS - Asia 47
SA - Sud America 3
AF - Africa 2
Totale 449
Nazione #
US - Stati Uniti d'America 181
IT - Italia 64
CN - Cina 24
FR - Francia 23
IE - Irlanda 22
GB - Regno Unito 19
IN - India 14
NL - Olanda 14
SE - Svezia 14
DE - Germania 10
GR - Grecia 7
BA - Bosnia-Erzegovina 6
CA - Canada 4
PL - Polonia 4
RS - Serbia 4
SG - Singapore 4
SI - Slovenia 4
ES - Italia 3
HR - Croazia 3
MX - Messico 3
AT - Austria 2
BR - Brasile 2
CH - Svizzera 2
DK - Danimarca 2
KR - Corea 2
ME - Montenegro 2
NG - Nigeria 2
UA - Ucraina 2
AM - Armenia 1
AR - Argentina 1
HU - Ungheria 1
IL - Israele 1
JP - Giappone 1
RO - Romania 1
Totale 449
Città #
Chandler 46
Dublin 22
Milan 14
Amsterdam 12
Nyköping 11
Rome 7
Banja Luka 6
London 6
Paris 6
Preveza 6
Ashburn 5
Chaponost 5
Medford 5
Mumbai 5
Princeton 5
Turin 5
Belgrade 4
Brookline 4
Fairfield 4
Hangzhou 4
Jacksonville 4
Newcastle upon Tyne 4
Torino 4
Beijing 3
Chennai 3
Coyoacán 3
Genay 3
Singapore 3
Toulouse 3
Vancouver 3
Zagreb 3
Abuja 2
Andover 2
Atlanta 2
Bengaluru 2
Birmingham 2
Boston 2
Cambridge 2
Celje 2
Chengdu 2
Dearborn 2
Dossobuono 2
Flanders 2
Fuzhou 2
Genoa 2
Hebei 2
Houston 2
Hyderabad 2
Lake Villa 2
Lenart v Slov. Goricah 2
Madrid 2
Messina 2
Mutterstadt 2
New Delhi 2
New York 2
Nuremberg 2
Padova 2
Philadelphia 2
Phoenixville 2
Pomezia 2
San Francisco 2
Seoul 2
Sevenoaks 2
Shenzhen 2
Stockholm 2
Tarbes 2
Vejle 2
Westfield 2
Woodstock 2
Ann Arbor 1
Brooklyn 1
Budapest 1
Calgary 1
Cardito 1
Cluj-Napoca 1
Coventry 1
Ferrara 1
Frattamaggiore 1
Fremont 1
Geneva 1
Guiyang 1
Gunzenhausen 1
Hellikon 1
Hopkins 1
Kettering 1
Krakow 1
Kunming 1
Lancaster 1
Mannheim 1
Milanówek 1
Monmouth Junction 1
Norwalk 1
Parma 1
Petah Tikva 1
Quanzhou 1
Quartu Sant'elena 1
Redwood City 1
Rescaldina 1
Rotterdam 1
San Diego 1
Totale 325
Nome #
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 254
Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial 71
Expected and paradoxical effects of obesity on cancer treatment response 53
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes 46
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 34
Totale 458
Categoria #
all - tutte 1.327
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.327


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202023 0 1 1 2 3 3 6 2 1 1 3 0
2020/202126 0 1 0 0 1 0 1 1 12 4 3 3
2021/202258 3 1 2 1 4 4 5 3 2 4 19 10
2022/2023223 22 19 5 14 13 34 20 21 33 16 14 12
2023/2024128 13 32 15 9 11 15 7 12 1 11 2 0
Totale 458